Q1 2027 Biocon Ltd Earnings Call Transcript
Key Points
- Biocon Ltd (BOM:532523) reported 10% year-on-year growth in operating revenue, with biopharmaceuticals growing 17%.
- The generics business delivered strong growth of 21% year-on-year, with EBITDA margin improving by over 250 basis points.
- Biosimilars revenue grew 16% year-on-year, driven by North America, with EBITDA margin at 25%.
- The company successfully launched several key products, including denosumab biosimilar, aflibercept (Yesafili), and generic liraglutide in the U.S.
- Interest costs declined 23% year-on-year, and reported net profit before exceptionals increased 245% year-on-year.
- The company received EMA approval for a second drug product line at its Malaysia insulin facility, supporting future growth.
- Management highlighted a favorable policy environment for biosimilars in the U.S., with potential to simplify development and adoption.
- The company is focused on profitable growth, with a strategic approach to R&D and cost optimization, not cutting muscle but fat.
- Legacy biosimilar products like Fulphila and Ogivri continue to deliver strong margins and market share, demonstrating enduring value.
- The company has a pipeline to launch at least one new product in the U.S. or Europe every year through the end of the decade.
- Service revenues (Syngene) declined 16% year-on-year due to lower offtake from a key biologics client and a forex hedge loss.
- Syngene's performance is expected to be a transition year, with single-digit revenue de-growth and EBITDA margins returning to mid-20s only by FY28.
- Net debt increased sequentially by around INR1,100 crore due to higher working capital, primarily inventory buildup for second-half scale-up.
- The generics business EBITDA margin remains low at 7%, with R&D spend reduced, indicating potential underinvestment in future growth.
- The company faces competitive intensity and price erosion in the biosimilars market, which could pressure margins.
- The biosimilars business EBITDA margin of 25% is lower than the normalized 27% of last year, indicating potential margin pressure.
- The company's growth is heavily dependent on new launches, which may take time to ramp up, with meaningful acceleration only expected in the second half.
- The U.S. tariff announcement, though currently not applicable, poses a potential risk to the business, requiring monitoring.
- The company's investment in new manufacturing units is still in scaling-up phase, with cost drag expected to continue.
- The company's focus on profitable growth may limit aggressive market share gains, potentially slowing revenue growth in the near term.
Thank you, Nidav, and good morning, everyone. Thank you for joining us today to discuss Biocon's first quarter results for financial year 2027. A press release and presentation related to the same have been sent to the exchanges and are uploaded on our website for your reference.
Let me introduce the management team on this call. We are joined by Biocon Chairperson Dr. Kiran Mazumdar-Shaw; Mr. Kedar Upadhye, CFO, along with other senior members of our management team. We will begin with opening remarks from Kiran, following which we will open the call for questions. Please note that this call is being recorded. The recording will be made available on our website within a day and the call transcript will be shared shortly thereafter.
Before we begin, I want to remind everyone about the Safe Harbor related to today's call. Comments made during the call may be forward-looking in nature and must be viewed in relation to the risks that our business faces that could cause our future results, performance, or achievements to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
